Pharnext, Tasly to form drug combo JV

Pharnext S.A.S. (Euronext:ALPHA) and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) will form a JV to develop combination therapies integrating Tasly's traditional Chinese medicines and Pharnext's drug combination formulations, primarily in cardiovascular and oncology indications.

Pharnext will have 30% ownership of the JV, which will be based in Tianjin, China...